- AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
- AlloVir Reports Full Year 2020 Financial Results
- AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
- AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
- AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses
- Company Profile for AlloVir
- Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting
- Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy
More ▼
Key statistics
On Friday, Allovir Inc (ALVR:NSQ) closed at 36.56, -25.33% below its 52-week high of 48.96, set on Dec 23, 2020.
52-week range
Markit short selling activity
Open | 40.54 |
---|---|
High | 41.73 |
Low | 35.71 |
Bid | 37.00 |
Offer | 41.00 |
Previous close | 40.20 |
Average volume | 248.31k |
---|---|
Shares outstanding | 65.11m |
Free float | 27.46m |
P/E (TTM) | -- |
Market cap | 2.38bn USD |
EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of Feb 26 2021 21:00 GMT.
More ▼